Becton, Dickinson and Company
Becton, Dickinson and Company (BD) stands as the global market leader in the vascular access device and accessories market, a position significantly bolstered by its strategic 2017 acquisition of C.R. Bard. The company leverages its extensive portfolio and vast global presence across 61 countries through its BD Medical and BD Interventional segments. BD’s core strength in vascular access is evident in its dominance across multiple device categories. In the U.S. market, BD is the overall leader in both Peripherally Inserted Central Catheters (PICCs) and Peripheral Intravenous Catheters (PIVCs). Their comprehensive PIVC offerings include products like the BD Insyte Autoguard and the BD Cathena Safety IV Catheter, all focused on patient safety and reducing the risk of needlestick injury. For PICCs, the company’s PowerPICC™ and PowerPICC Provena™ lines, acquired from C.R. Bard, provide high-performance, power-injectable central venous access. Additionally, BD offers a variety of central venous catheters, dialysis catheters, ports, and midline catheters (like the PowerGlide™) through its Medical delivery solutions and Peripheral intervention units. The company’s continuous investment in R&D and focus on integrating innovative patient safety and infusion technology are central to maintaining its market leadership and enhancing patient outcomes globally.
Latest Market Research Report on Vascular Access Device Download PDF Brochure Now
Teleflex Incorporated
Teleflex Incorporated is a leading global provider of medical technologies and a major force in the vascular access device market, distinguished by its Arrow-branded products. The company’s strong position is largely due to its 2007 acquisition of Arrow International, which established its dominance in Central Venous Catheters (CVCs) and other key segments. Teleflex is a leader in a diverse range of vascular access products, including Peripherally Inserted Central Catheters (PICCs), midlines, dialysis catheters, and advanced tip-placement devices. Their commitment to innovation is supported by significant R&D investment, leading to the continuous launch of new products. For instance, the company is known for its line of power-injectable PICCs, such as the Arrowg+ard Blue Advance PICC, and has recently expanded its offerings with the introduction of the Arrow Pressure Injectable Midline Catheter in markets like Australia and New Zealand. Furthermore, Teleflex has expanded its portfolio into vascular closure technology with the MANTA Vascular Closure Device, a biomechanical solution for closing large bore femoral arterial access sites. By securing key group purchasing agreements and consistently expanding its market presence with advanced devices, Teleflex continues to solidify its role as a key global partner for clinicians requiring reliable and innovative vascular access solutions.
B. Braun SE
B. Braun SE, headquartered in Germany, is a globally recognized medical device and pharmaceutical company with a deep commitment to patient and procedural safety, positioning it as a top player in the vascular access device market. The company’s expertise is focused on delivering a wide range of high-quality, precision-engineered products, including catheters, guidewires, and closure devices, to hospitals and cardiac centers worldwide. B. Braun holds a significant position in the U.S. Peripheral Intravenous Catheter (PIVC) market, often ranking as the second-largest leader by leveraging a strategy of offering high-quality products at a competitive price point to drive unit sales volume. Its key PIVC products, such as the Introcan Safety IV Catheters and the Introcan Safety 3 Closed IV Catheters, exemplify the company’s focus on safety features designed to prevent needlestick injuries and enhance clinical workflows. The company’s robust infrastructure, which emphasizes precision manufacturing and localized supply chain strategies, ensures reliable product availability for clinicians. By adhering to a philosophy of “Sharing Expertise,” B. Braun provides essential infrastructure and solutions that support efficient and reliable vascular access procedures, reinforcing its role as a critical, long-standing global supplier of medical technology.
ICU Medical, Inc.
ICU Medical, Inc. is a key global player in the vascular access device market, distinguished by its comprehensive and strong product portfolio, particularly in the Consumables and Infusion Systems segments. The company offers a wide array of vascular access devices and accessories, including various types of central venous catheters (CVCs), peripheral IV catheters, needle-free connectors, and intraosseous needles. A transformative moment for ICU Medical’s presence in this market was the completion of its acquisition of Smiths Medical from Smiths Group plc in January 2022. This strategic move significantly broadened the company’s offering to include Smiths Medical’s infusion devices, vascular access, and vital care products, instantly creating a leading infusion therapy company with an expanded global market reach across the Americas, Europe, and Asia Pacific. ICU Medical is known for producing high-quality products that undergo rigorous testing to ensure reliability and performance, meeting stringent regulatory standards. By leveraging the combined strengths of its original product lines and the acquired Smiths Medical portfolio, ICU Medical provides clinicians with a robust suite of integrated, high-quality products necessary for safe and effective patient care, solidifying its position in the competitive vascular access landscape.
AngioDynamics
AngioDynamics, Inc. is a global medical technology company focused on providing minimally invasive, platform technology-enabled medical devices for vascular and oncology applications, making it a significant player in the specialized vascular access device market. The company concentrates on delivering targeted solutions for complex procedures, particularly in neurovascular and peripheral angiographic interventions, which rely on precise and advanced vascular access. Its strategic focus includes advanced thrombectomy and catheter technologies. Notably, in 2024, AngioDynamics streamlined its product portfolio by divesting its PICC and midline product lines to Spectrum Vascular. This strategic divestiture, valued at $45 million, was designed to allow the company to concentrate its resources on higher-growth segments and improve overall financial performance, highlighting a focus on specialized, high-margin vascular access technologies. The company is committed to innovation and actively adapts its product development to align with shifting regulatory landscapes and evolving clinical needs. By focusing on its core strengths in advanced vascular interventions and simplifying its product set, AngioDynamics reinforces its role as a nimble and essential provider of specialized devices that support complex, minimally invasive therapeutic access.
Latest Market Research Report on Vascular Access Device Download PDF Brochure Now